Towards novel treatment options in von Willebrand disease - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Haemophilia Année : 2022

Towards novel treatment options in von Willebrand disease

Peter J. Lenting
Claire Kizlik-Manson
  • Fonction : Auteur
Caterina Casari
  • Fonction : Auteur

Résumé

Abstract Deficiency or dysfunction of von Willebrand factor (VWF) is associated with a bleeding disorder known as von Willebrand disease (VWD). The clinical manifestations of VWD are heterogeneous, and are in part dictated by the structural or functional defects of VWF. The tools to control bleeding in VWD are dominated by VWF concentrates, desmopressin and antifibrinolytic therapy. In view of these treatments being considered as effective, it is surprising that quality‐of‐life studies consistently demonstrate a significant mental and physical burden in VWD patients, particularly in women. Apparently, the current weaponry to support the management of VWD is insufficient to fully address the needs of the patients. It is important therefore to continue to search for innovative treatment options which could better serve the VWD patients. In this short review, two of such options are discussed in more detail: emicizumab to correct for the deficiency of factor VIII (FVIII), and the pegylated aptamer BT200 to increase endogenous levels of the VWF/FVIII complex.
Fichier principal
Vignette du fichier
Lenting et al novel VWF treatments Haemophilia 2022 clean.pdf (1.28 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04456557 , version 1 (14-02-2024)

Identifiants

Citer

Peter J. Lenting, Claire Kizlik-Manson, Caterina Casari. Towards novel treatment options in von Willebrand disease. Haemophilia, 2022, 28 (S4), pp.5-10. ⟨10.1111/hae.14518⟩. ⟨hal-04456557⟩
6 Consultations
10 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More